US Patent Issued to THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH on March 4 for "Combined sirolimus and nintedanib therapy for vascular lesions and hereditary hemorrhagic telangiectasia" (New York Inventor)

ALEXANDRIA, Va., March 5 -- United States Patent no. 12,239,636, issued on March 4, was assigned to THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (Manhasset, N.Y.).

"Combined sirolimus and nintedanib therapy for vascular lesions and hereditary hemorrhagic telangiectasia" was invented by Philippe Marambaud (Astoria, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods and pharmaceutical compositions comprising one or more mTOR inhibitors such as sirolimus and one or more receptor tyrosine kinase inhibitors such as nintedanib are disclosed for treating vascular lesions and hereditary hemorrhagic telangiectasia."

The patent was filed on Sept. 24, 2019, under Application No. 17/274,725.

*For further inf...